Eiger BioPharmaceuticals, Inc. (EIGR) At $12.20 Forms Bottom; Dividend & Income Fund (DNI) Sentiment Is 1.43

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

Eiger BioPharmaceuticals, Inc. (EIGR) formed multiple bottom with $11.10 target or 9.00% below today’s $12.20 share price. Eiger BioPharmaceuticals, Inc. (EIGR) has $167.58M valuation. The stock increased 0.83% or $0.1 during the last trading session, reaching $12.2. About 99,042 shares traded. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has risen 88.41% since July 1, 2017 and is uptrending. It has outperformed by 75.84% the S&P500. Some Historical EIGR News: 25/05/2018 – EIGER BIOPHARMACEUTICALS CONFIRMS OFFERING PRICE $12.50/SHARE; 23/04/2018 – European Medicines Agency Validates Type Il Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3…; 21/03/2018 – EIGER BIOPHARMACEUTICALS INC – EXPECT TO SHARE ADDITIONAL INFORMATION ON PLANNED REGISTRATION PROGRAM IN 2Q 2018; 16/05/2018 – EIGER TO SEEK FDA GUIDANCE TO APPROVE LONAFARNIB IN PROGERIA; 21/03/2018 – EIGER: POSITIVE GUIDANCE ON HEPATITIS DELTA VIRUS REGISTRATION; 06/03/2018 Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March; 24/05/2018 – Eiger BioPharmaceuticals Sees $37.2 Million in Net Proceeds From Offering; 16/05/2018 – Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF); 23/04/2018 – DJ Eiger BioPharmaceuticals Inc, Inst Holders, 1Q 2018 (EIGR); 17/04/2018 – Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-lnfected Patients at The International Liver Congress™ 2018

Dividend & Income Fund (DNI) investors sentiment decreased to 1.43 in 2018 Q1. It’s down -0.15, from 1.58 in 2017Q4. The ratio dropped, as 20 hedge funds opened new or increased holdings, while 14 decreased and sold their holdings in Dividend & Income Fund. The hedge funds in our database now own: 3.96 million shares, up from 3.37 million shares in 2017Q4. Also, the number of hedge funds holding Dividend & Income Fund in top ten holdings was flat from 1 to 1 for the same number . Sold All: 6 Reduced: 8 Increased: 14 New Position: 6.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on August, 13. They expect $-0.82 EPS, up 38.35% or $0.51 from last year’s $-1.33 per share. After $-0.84 actual EPS reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -2.38% EPS growth.

The stock increased 0.41% or $0.05 during the last trading session, reaching $12.33. About 22,408 shares traded. Dividend and Income Fund (DNI) has risen 1.23% since July 1, 2017 and is uptrending. It has underperformed by 11.34% the S&P500.

Blue Bell Private Wealth Management Llc holds 2.6% of its portfolio in Dividend and Income Fund for 472,308 shares. Bulldog Investors Llc owns 101,000 shares or 0.35% of their US portfolio. Moreover, Highland Capital Management Lp has 0.15% invested in the company for 230,968 shares. The New Jersey-based Landscape Capital Management L.L.C. has invested 0.11% in the stock. Saba Capital Management L.P., a New York-based fund reported 138,076 shares.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Chart